Objective: While sex differences in the treatment and outcomes of subjects with acute coronary syndromes are well documented, little is known about the impact of cardiac troponin (cTn) levels obtained in the emergency department (ED) on the observed sex differences. We sought to determine whether cTn levels by chest pain features modify sex differences in diagnosis, treatment, and outcomes in patients presenting with chest pain suggestive of ischemia.
was cardiac in nature; males filled 25% more prescriptions for statins than their female counterparts. Adjustment for baseline differences did not attenuate this difference.
Conclusions: Sex differences in diagnosis and treatment after presentation to the ED with chest pain are not explained by differences in chest pain features or levels of cTn. Even when females have cardiac chest pain and cTn levels > 99th percentile, they are less likely to be diagnosed with MI, less likely to undergo diagnostic cardiac catheterization within 7 days, and less likely to use evidence-based cardiac medications, but they have the highest 1-year MACE rate. The higher MACE rate appears to be driven by the higher burden of comorbid conditions. S everal studies have identified sex differences in treatment and outcomes of patients with a confirmed diagnosis of acute coronary syndromes (ACS). [1] [2] [3] [4] Less is known about the sex differences in the diagnosis, treatment, and outcomes of patients presenting to emergency department (ED) with chest pain suggestive of ischemia. Prior studies suggest that women presenting to ED with chest pain suggestive of cardiac ischemia are less likely to undergo diagnostic coronary angiography, less likely to be diagnosed with myocardial infarction (MI), 5, 6 and less likely to use cardiac medications than men after discharge. 7 Often, however, the impact of cardiac troponin (cTn) level, a protein complex that is a key element in diagnosis of MI, at the time of presentation to ED is not explored as a factor in understanding the observed sex differences in diagnosis and treatment.
Sex differences in cTn level may be a factor that affects the lower rate of MI diagnosis and treatment in women who present to ED with chest pain suggestive of cardiac ischemia. The universal definition of MI includes an elevated level of cTn with signs or symptoms consistent with myocardial ischemia. 8 With the availability of high-sensitivity cardiac troponin I assays (cTnI), it has become apparent that there are noteworthy sex differences in the 99th percentile of the cTn distribution, a cut point for the upper limit of normal, in healthy populations. 9 Specifically, the 99th percentile is lower in women than men, suggesting that with the use of a single cut point, women with MI may be underdiagnosed because the threshold is too high. It is unknown whether the threshold for "sensitive" fourth-generation cTn should be lower in women; if women are missed because the troponin threshold is too high, then more women in the "<99th percentile" group would be expected to have adverse outcomes than men in this group. 10 As such, in this retrospective cohort study, we sought to determine whether cTn levels modify sex differences in diagnosis, cardiac catheterization, major adverse cardiac events (MACE), and postdischarge cardiac medication use in patients presenting to the ED with chest pain suggestive of ischemia.
METHODS Population
St. Paul's Hospital (SPH), a university-affiliated innercity hospital, and Mount St. Joseph (MSJ), a community hospital, are in Vancouver, British Columbia, with 75,000 and 25,000 annuals ED visits, respectively. Consecutive British Columbians (≥20 years) who presented to the ED of these two hospitals and were assessed for a chief complaint of ischemic chest pain between May 1, 2008, and March 30, 2013, were included. Subjects were excluded if the chest pain was unlikely to be ischemic in nature, as described below. The study population included both patients who presented to ED and were discharged from ED without being admitted to the hospital and those who were subsequently admitted. Additional exclusions are described in Figure 1 . If a patient had more than one ED visit during the study period, only the first ED visit was used in the evaluations.
In the province of British Columbia, Canada, two sensitive cTn tests (Siemens cTnI) were used at SPH and MSJ hospitals from May 2008 through March 2013: Siemens Centaur, Siemens Healthcare Diagnostics-99th percentile reference limit 0.04 ng/mL, limit of quantitation 0.02 ng/mL, 10% coefficient of variation at 0.03 ng/mL; Siemens Stratus CS Acute Care Diagnostic System, Siemens Healthcare Diagnostics99th percentile reference limit 0.07 ng/mL, limit of quantitation 0.03 ng/mL, 10% coefficient of variation at 0.06 ng/mL. Numerical cTnI values were reported even if the level was below the 99th percentile, thus allowing us to create three categories of cTnI level, as described below.
Definitions
• cTnI levels: based on peak levels of cTnI within 24 hours of presentation to the ED. The peak cTnI values were grouped into three levels: below the limit of quantitation (<LOQ), above the limit of quantitation, but below the 99th percentile (quantified normal values), and above the 99th percentile (>99th percentile).
• Chest pain (CP) categories: used in the standardized, reproducible, validated Canadian Emergency Department Triage and Acuity Scale (CTAS) coding in the ED [11] [12] [13] and grouped into two categories: chest pain with cardiac features or history (cardiac), chest pain with respiratory symptoms (respiratory) which are consistent with ischemic presentation. These two categories were also combined to form the ischemic chest pain group.
-Cardiac category: CP + cardiac features; CP + resolved, significant cardiac history.
-Respiratory category: CP + moderate respiratory distress; CP + respiratory symptoms, looks unwell; CP + respiratory symptoms, looks well; CP + severe respiratory distress.
• The following chest pain categories were excluded from the analysis: CP + noncardiac features or history; CP + minor chest injury and minimal/no respiratory distress; CP + moderate hemodynamic compromise; CP + severe hypotension or shock; CP, ripping, or tearing, noncardiac features.
• MACE: all-cause mortality, admission to hospital for MI, incident admission for heart failure (HF) or for angina requiring diagnostic catheterization or revascularization, within 1 year of the discharge from the index ED presentation. Discharge could be from the ED directly or from hospital for subjects who were admitted to hospital from the ED.
• Medication use within 90 days of ED/hospital discharge was defined as filling at least one prescription for:
-Angiotensin-converting enzyme inhibitor (ACE-I)/angiotensin receptor blocker (ARB).
-Beta-blockers (BB).
-Statins.
Data Sources
The Vancouver Coast Health Authority ED database was used to identify consecutive chest pain patients using the CTAS code, which is a reliable, validated 5- 11 where a level 1 patient requires resuscitation and a level 5 patient is deemed nonurgent. The Sunrise Information System (Sunrise Information Systems) was queried to obtain the cTnI test results for these patients. The provincial hospital Discharge Abstract Database (DAD) 14 was used to identify comorbid conditions, as well as cardiac catheterization and coronary revascularization procedures and admission to hospital for MI, HF, or angina; the provincial Medical Services Plan (MSP) database, 15 which covers all services provided by all physicians, was also used to identify comorbid conditions. Medication use, 90 days prior to the ED visit and 90 days postdischarge, was identified from the British Columbia PharmaNet database, 16 which collects all prescriptions for drugs dispensed from community and hospital outpatient pharmacies. Deaths were obtained from the BC Vital Statistics database, 17 and BC residency was established using the Client Registry database. 18 
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Statistical Methods
Baseline demographic and clinical characteristics of females and males for each cTnI level were examined using counts and percentages for categorical variables. Comorbidities were identified from diagnosis codes reported in DAD and MSP going back 3 years from the date of the index ED visit. Age was summarized using median and first and third quartiles, as well as grouped into ≤65 and >65 years old.
Hospital admissions within 24 hours of an ED visit were linked to identify patients presenting with an MI in the ED using the ICD10 diagnosis codes, I21.xx and I22.xx. Patients with cTnI > 99th percentile who were admitted to hospital were further explored to identify the most responsible diagnosis (MRD) codes.
The cumulative event rates for the composite MACE endpoint were estimated for each sex and cTnI level using the Kaplan-Meier method and compared using the log-rank test. The Cox model was used to estimate the unadjusted and adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for 1-year MACE for sex by cTnI levels. The proportional hazard assumption was assessed by Schoenfeld residuals plots. Factors included in the adjusted model were selected a priori based on clinical input: chest pain categories, age (≤50, 50-80, >80 years), CTAS level 1 or 2 (resuscitation or emergent status) at ED presentation, an ED diagnosis of MI, as well as comorbid conditions: hypertension, diabetes, prior stroke, liver disease, HF, chronic renal disease, atrial fibrillation (AF), peripheral vascular disease (PVD), chronic obstructive pulmonary disease (COPD), and prior MI.
The proportion of diagnostic cardiac catheterization within 7 days of the ED visit was estimated for each sex and sex by cTnI level combination. Logistic models for 7-day catheterization were fit unadjusted and adjusted for the same comorbidities as in the MACE model.
Statin, BB, and ACE-I/ARB use within 90 days after discharge was examined with respect to use prior to the index ED visit versus no prior use, where prior use was defined as having filled a prescription within 90 days before ED visit. Univariate comparisons of medication use over all chest pain categories (i.e., ischemic chest pain) and individually by sex at each cTnI level were tested using a chi-square test. For each medication, the odds of filling a prescription within 90 days of discharge was examined by fitting logistic regression models for sex, cTnI levels, chest pain categories (overall and by each category), medication use 90 days prior to ED visit, and all two-way interactions among these factors. Adjusted models additionally included the following comorbidities: age, hypertension, diabetes, prior stroke, liver disease, AF, HF, COPD, chronic renal disease, PVD, and prior MI. These potential confounders were selected a priori based on clinical input. Statistical analyses were performed using SAS software, version 9.4.
RESULTS
Over the 5-year study period, 25,539 patients presented to the ED with chest pain of which 7,272 (2,933 females and 4,339 males) met the inclusion criteria and were included for the MACE analysis (Figure 1) . The distribution of patients by cTnI levels, sex, and chest pain categories, as well as the patients' characteristics by sex and cTnI levels, is presented in Tables 1 and 2 , respectively. Overall the majority of patients had cTnI levels that were <LOQ (females 80.9% vs. males 70.4%). Furthermore, among those with cardiac chest pain, 21.0% of males compared to only 12.2% of females had cTnI levels > 99th percentile.
Baseline characteristics of subjects presenting to the ED with ischemic chest pain, stratified by sex and cTnI levels, are shown in Table 2 . Females were older and had more hypertension, history of HF, and chronic renal disease irrespective of cTnI level. However, females with quantified normal values of cTnI had the greatest burden of comorbidities with higher likelihood of having a history of hypertension, liver disease, AF, COPD, and chronic renal disease. Of note, among patients with cTnI > 99th percentile, males (52.5%) were more likely to be diagnosed with MI within 24 hours of ED presentation than females (35.4%). Similar findings were observed when patients with cTnI > 99th percentile were stratified by chest pain categories ( Figure 2) ; the proportion of men receiving a MRD diagnosis of MI exceeded that in women (39.7% vs. 53.1%). Even among these patients who presented with chest pain with cardiac features/ history, females were less likely to be diagnosed with MI (46.4% vs. 57.5%). Among patients with chest pain with cardiac features/history and cTnI levels > 99th percentile, who were not admitted with a diagnosis of MI, the most common diagnoses were chronic ischemic heart disease (ICD-10 code I25) and ACE-I = angiotensin-converting enzyme inhibitors; AF = atrial fibrillation; ARB = angiotensin II receptor blocker; BB = beta-blocker; cTnI = cardiac troponin I; CTAS = Canadian Triage and Acuity Scale; COPD = chronic obstructive pulmonary disease; CP = chest pain; HF = heart failure; MI = myocardial infarction; PVD = peripheral vascular diseases. *Counts suppressed for patient confidentiality (n < 6).
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HF (ICD-10 code I50) (Data Supplement S1, available as supporting information in the online version of this paper, which is available at http://onlinelibrary.wiley.c om/doi/10.1111/acem.13371/full).
MACE
Within the first year following ED or hospital discharge, 643 subjects had a MACE. The cumulative MACE event curves to 1 year, by cTnI level and sex, are shown in Figure 3 . Females in the cTnI > 99th percentile group had the worst outcomes with a 1-year In contrast, among those with cTnI levels <LOQ, the MACE rate was significantly lower in females than males, even after adjustment for baseline differences (Table 3) . While the unadjusted MACE hazard ratio was higher in females with cTnI levels > 99th percentile compared to males (unadjusted HR = 1.24, 95% CI = 0.94-1.65), it did not reach statistical significance; after adjustment for baseline differences no sex difference was observed in MACE (adjusted HR = 0.97, 95% CI = 0.73-1.29).
Although postdischarge hospitalization for diagnostic cardiac catheterization, with or without revascularization, was included as one of the components of MACE, we separately also explored sex differences in undergoing a diagnostic cardiac catheterization within 7 days of the ED visit. Overall, females underwent fewer catheterizations than males (7.9% vs. 16 Figure 3 . Cumulative MACE after ED/hospital discharge to 1 year by sex and cTnI level. <LOQ = below the limit of quantitation; MACE = major adverse cardiac event (death, MI, incident heart failure, or angina hospitalization); cTnI = cardiac troponin I. ratio [OR] = 0.52, 95% CI = 0.39-0.70). After adjustment for baseline differences, as well as diagnosis of MI in the ED, females were still less likely to undergo diagnostic catheterization (OR = 0.67, 95% CI = 0.45-1.00).
Utilization of Evidence-based Cardiac Medications
To examine the impact of cTnI level on cardiac medication use after ED discharge to assess treatment strategies, additional exclusions were made to ensure patients had sufficient time to fill prescriptions after discharge and there were no contraindications for medication use ( Figure 1 ). As such 6,907 patients (2,820 females, 4,087 males) were included in this analysis. Within 90 days of discharge from the ED/ hospital, females were less likely to use the evidencebased cardiac medications-ACE-I/ ARBs, BB, or statins-irrespective of cTnI level or chest pain type (Figure 4) , with the exception of ACE-I/ARB and BB use among patients with quantified normal values of cTnI whose CP had respiratory features. The most striking sex differences were noted when cTnI levels were cTnI > 99th percentile and when the chest pain was cardiac in nature with males having filled 25% more prescriptions for statins than their female counterparts.
When postdischarge medication use was examined based on whether the medication was prescribed prior to the ED visit (prior) or not (no prior), the most significant sex differences, favoring medication use in males, were seen when the chest pain was cardiac in nature and no prior medication use (Figure 4) . Furthermore, the highest ORs (favoring males) were when the patients had cTnI level > 99th percentile for each three classes of medications ( Figure 5 ; female vs. male Among patients who had been on the selected medications prior to the ED visit, no significant sex differences were observed, except for statins-more prescriptions were filled among male patients with cardiac chest pain and cTnI levels > 99th percentile than female patients with the same presentation (unadjusted female vs. male OR = 0.47, 95% CI = 0.31-0.72). Among patients who had chest pain with respiratory symptoms and cTnI levels <LOQ, ACE-I/ ARB use was significantly higher in females (unadjusted female vs. male OR = 1.97, 95% CI = 1.33-2.90).
DISCUSSION
To our knowledge, this is the first study to examine the impact of cTn level on sex differences in diagnosis, adverse cardiac events, and medication use following an ED visit for ischemic chest pain. We found that among patients triaged as chest pain with cardiac features and with peak cTnI levels > 99th percentile, females were significantly less likely to be diagnosed with MI, to use evidence-based cardiac medications, and to access cardiac catheterization, but they had the highest crude rate of MACE, even relative to males with the same levels of cTnI. The observed sex difference in those with cTnI levels > 99th percentile was explained by differences in baseline comorbidities and therefore was not statistically significant after adjustment for baseline differences. The use of evidence-based cardiac medications was lower in females than males, irrespective of cTnI levels. Of note, among females with cTnI levels > 99th percentile, the rates of ACE-I/ARB, BB, and statin use were significantly lower, compared to their male counterparts, but these females experienced the highest MACE rates over the 1-year followup period.
The finding that females with ischemic symptoms are less likely to be diagnosed with MI has been documented in the literature. It has been suggested that the lower rate of MI diagnosis in females may be due to sex differences in presentation with females being less likely to present with typical cardiac chest pain, 19 although this difference is attenuated with older age. It has also been suggested that females may be less likely cTnI = cardiac troponin I; HR = hazard ratio; MACE = major adverse cardiac event. *Adjusted for chest pain categories, age, resuscitation/emergent Canadian Triage and Acuity Scale score, myocardial infarction diagnosis at ED presentation, hypertension, diabetes, prior stroke, liver disease, heart disease, atrial fibrillation, chronic renal disease, chronic obstructive pulmonary disease, prior myocardial infarction, and peripheral vascular disease. †Statistically significant HR.
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to have cTn levels consistent with MI. 20, 21 Our assessment of MI does not allow us to distinguish between type I and type II MI, given that this information is lacking in administrative data and type II MIs are rarely coded as "MI" in these data holdings. 22 It is thus possible that both females and males assessed as type II MI were not coded as "MI" in the administrative data.
Our study adds important new information, namely, that the lower rate of MI diagnosis in females does not appear to be related to differences in chest pain presentation or levels of cTnI. Even among patients whose chest pain was assessed as cardiac in nature and whose cTnI levels were above the 99th percentile, females were still significantly less likely than males to be diagnosed with AMI. While women in this category were more likely to be diagnosed with HF than men, this diagnosis represents only a small proportion and thus does not explain the lower rate of MI diagnoses among women. There are very few studies that have evaluated the sex differences in adverse cardiac events among patients presenting to ED with suspected cardiac ischemia, according to cTn levels. Our finding that females with cTn levels > 99th percentile and cardiac chest pain had the highest event rates, needs to be interpreted with caution. We are unable to determine whether our subjects had type I or type II MI or non-MI acute myocardial injury. Furthermore, we cannot determine whether the type of myocardial injury varied by sex and how this may have contributed to the observed sex difference. Finally, the sex difference was attenuated after adjustment for baseline differences, suggesting that a greater comorbid burden in women was responsible for some of the observed differences.
Using a lower diagnostic threshold for sensitive cTnI assay than the standard level of ≥0.20 ng/mL, Mills and colleagues 23 found that among patients who presented to ED at the Royal Infirmary of Edinburgh, United Kingdom, with suspected ACS, 39% of patients with cTnI 0.05 to 0.19 ng /mL died or had recurrent MI within the first year, compared with 24% of patients with cTnI 0.20 ng/mL or greater. This seeming paradox may be explained by the fact that patients with cTnI levels < 0.20 ng/mL were likely discharged without ACS-specific treatment, while those above this threshold most likely had appropriate ACS treatment. An analysis by sex was not reported and, as such, it could not be determined if this observation varied by sex. Although we did not observe a higher MACE rate among patients with quantified normal values of cTn, compared to those with cTn > 99th percentile; nevertheless, our study indicates that patients with levels of troponin above the limit of quantitation, but lower than the 99th percentile cut point, are not a group with benign outcomes. Their MACE rates (for both men and women) were only slightly below the MACE rate observed among those with cTn levels > 99th percentile. We did not observe any sex differences in 1-year MACE among patients with quantified normal values of cTn, but this may due to the small number of subjects in this group.
Overall, females were half as likely to undergo cardiac catheterizations within 7 days. Even among patients with cardiac chest pain and cTn > 99th percentile, 48.4% of females underwent a diagnostic catheterization compared to 64.3% of males. This finding suggests that neither chest pain type nor cTn levels explain the lower rates of cardiac catheterization in females compared to males.
With respect to evidence-based cardiac medication use, we observed sex gaps similar to those previously noted by other investigators, specifically among patients diagnosed with ACS. 24 Using the Global Registry of Acute Coronary Events, Nguyen et al. 25 showed that use of aspirin and statin in women was consistently lower than in men. Similarly, a study by Bugiardini et al., 7 based on the Canadian Acute Coronary Syndrome Registries, demonstrated that women were less likely to receive lipid lowering medications or ACE-I, compared to men, even after adjusting for baseline differences. Our findings add to this prior knowledge by demonstrating that the observed sex gap exists irrespective of cTn level or chest pain type and is most pronounced when cTn levels are diagnostic for MI (>99th percentile) and when the chest pain is cardiac in nature. What our study cannot determine is whether these differences are due to physicians' prescribing behavior or due to differences in patients' adherence with treatment recommendations.
LIMITATIONS
Our study has several limitations. First, we included only patients who presented with chest pain and as such our findings are not generalizable to patients with ischemia who may have presented without chest pain symptoms. Second, we only included two EDs in British Columbia, one a university-affiliated center, with specialized cardiac care, and the other a communitybased hospital. These were the only sites that recorded cTnI values below the 99th percentile cut point, but above the limit of quantitation, and therefore gave us the unique opportunity to evaluate the outcomes of patients with quantified normal values of cTn. We also acknowledge that our study used the results from two Siemens cTnI assays, with different diagnostic cut points, however, we believe that both would have comparable diagnostic capabilities in identifying patients with MI.
Another important limitation is our use of administrative data to identify MI. While type I MI is reliably coded in administrative data, type II MI and other forms of acute myocardial injury are not reliably coded as "MI." Furthermore, given the limitations of our laboratory data, specifically that we only had data for the first 24 hours, but not the actual time of the measurement, we were unable to assess whether there was a rise and/or fall; we could only determine the highest level. This limitation suggests we may have included subjects with chronic myocardial injury. We have mitigated this problem somewhat by only including the first visit within a 1-year period and only assessing acute ischemic chest pain presentations.
Medication use was defined based on filling at least one prescription within 90 days before and/or after ED/hospital discharge. With this definition we cannot determine whether the physician failed to prescribe the medications or whether the patient failed to fill the prescription. Among those who filled the prescription, we also could not verify if they took the medications as prescribed. Such additional information could provide a better understanding of the impact of patient and physician behavior on the observed sex differences in patients' treatment following ED discharge.
Our categorization of chest pain lacks important clinical granularity, but the CTAS is used in all EDs across Canada and demonstrates high interobserver agreement suggesting that the scale is understood and interpreted in a similar fashion by ED staff. Finally, as an observational study, our study results must be interpreted with caution, due to the potential for unmeasured confounding.
CONCLUSIONS
The sex difference in diagnosis and treatment after presentation to the ED with chest pain does not appear to be explained by differences in levels of cardiac troponin irrespective of chest pain features. Even when females have cardiac chest pain and cardiac troponin levels > 99th percentile, they are less likely to be diagnosed with myocardial infarction. Females with this presentation are also less likely than their male counterparts to undergo diagnostic cardiac catheterization within 7 days or to use evidence-based cardiac medications after discharge. Importantly crude major adverse cardiac event rates, after 30 days to 1 year are higher in females than males among those with cardiac troponin I levels > 99th percentile. However, these sex differences do not persist after adjustment for comorbid conditions. The BC's Ministry of Health and Vital Statistics Agency approved access and use of the data facilitated by Population Data BC. We thank the Population Data BC for facilitating this process. We also thank the BC Centre for Improved Cardiovascular Health for providing support for this study. The authors acknowledge the contributions of Patrick Daniele, Data Analyst, for his assistance with data manipulation and Melissa Pak, Research Manager, for coordinating all aspects of research.
